2014

The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Sane R, Wu SP, Zhang R, Gallo JM.
Drug Metabolism and Disposition: the Biological Fate of Chemicals 2014 Apr; 42(4).

Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors.
Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM.
CPT: Pharmacometrics & Systems Pharmacology 2014; 3.

A general network pharmacodynamic model-based design pipeline for customized cancer therapy applied to the VEGFR pathway.
Zhang XY, Birtwistle MR, Gallo JM.
CPT: Pharmacometrics & Systems Pharmacology. 2014 Jan 15;3:e92. doi: 10.1038/psp.2013.65.

2013

Mechanistic vs. empirical network models of drug action.
Birtwistle MR, Mager DE, Gallo JM.
CPT: Pharmacometrics & Systems Pharmacology. 2013 Sep 6;2:e72. doi: 10.1038/psp.2013.51.

Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.
Sharma J, Lv H, Gallo JM.
Cancer Research. 2013 Aug 15;73(16):5242-52.

Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.
Tiwari AK, Zhang R, Gallo JM.
Molecular Cancer Therapeutics. 2013 Jul;12(7):1343-55.

Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition.
Gallo JM.
Clinical Pharmacology & Therapeutics. 2013 Mar;93(3):236-8. doi: 10.1038/clpt.2012.244. Epub 2012 Dec 18.

Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.
Lv H, Zhang X, Sharma J, Reddy MV, Reddy EP, Gallo JM.
AAPS Journal. 2013 Jan;15(1):250-7. doi: 10.1208/s12248-012-9428-4. Epub 2012 Nov 22.

2012 

Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.
Lv H, Wang F, Reddy MV, Zhou Q, Zhang X, Reddy EP, Gallo JM.
Investigational New Drugs. 2012 Dec;30(6):2263-73. doi: 10.1007/s10637-012-9806-x. Epub 2012 Mar 1.

Activation of Alternate Pro-Survival Pathways Accounts for Acquired Sunitinib Resistance in U87MG Glioma Xenografts.
Zhou Q, Lv H, Mazloom AR, Xu H, Ma’ayan A, Gallo JM.
Journal of Pharmacology and Experimental Therapeutics. 2012 Nov;343(2):509-19. doi: 10.1124/jpet.112.196097. Epub 2012 Aug 6.

Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Sharma J, Lv H, Gallo JM.
Journal of Pharmaceutical Sciences. 2012 Nov;101(11):4100-6. doi: 10.1002/jps.23283. Epub 2012 Aug 1.

Merging systems biology with pharmacodynamics.
Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM.
Science Translational Medicine. 2012 Mar 21;4(126):126ps7.

2011

Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.
Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM.
Journal of Pharmaceutical and Biomedical Analysis. 2011 Dec 15;56(5):1117-20.

Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.
Wang Z, Zhou Q, Kruh GD, Gallo JM.
Drug Metabolism and Disposition. 2011 Nov;39(11):2155-61.

The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.
Zhou Q, Gallo JM.
AAPS Journal. 2011 Mar;13(1):111-20.

2010

Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.
Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G.
Molecular Pharmaceutics. 2010 Dec 6;7(6):2255-69.

Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors.
Wang F, Zhou F, Kruh GD, Gallo JM.
Neuro-Oncology. 2010 Oct;12(10):1043-9.

Pharmacokinetic/ pharmacodynamic-driven drug development.
Gallo JM.
Mt Sinai Journal of Medicine. 2010 Jul-Aug;77(4):381-8.

Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.
Zhou Q, Gallo JM.
Journal of Pharmaceutical and Biomedical Analysis. 2010 Mar 11;51(4):958-64.

2009

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic brain tumor model.
Zhou Q, Gallo JM.
Neuro-Oncology. 2009 Jun;11(3):301-10.

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.
Wang S, Zhou Q, Gallo JM.
Molecular Cancer Therapeutics. 2009 Jun;8(6):1438-47.

A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO.
Cancer Research. 2009 Jan 1;69(1):120-7.

2008

Impact of antiangiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Zhou Q, Guo P, Gallo JM.
Clinical Cancer Research. 2008 Mar 1;14(5):1540-9.

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Wang S, Guo P, Wang X, Zhou Q, Gallo JM.
Molecular Cancer Therapeutics. 2008 Feb;7(2):407-17.

2007

Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM.
Clin Cancer Res. 2007 Jul 15;13(14):4271-9.

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM.
Journal of Pharmacology and Experimental Therapeutics. 2007 Apr;321(1):265-75.

2004

Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P.
Clinical Cancer Research. 2004 Dec 1;10(23):8048-58.

2003

The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Gallo JM, Li S, Guo P, Reed K, Ma, J.
Cancer Research. 2003 Aug 15;63(16):5114-7.

Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide (TMZ) in subcutaneous and intracerebral human glioma xenograft models.
Ma J, Li S, Reed K, Guo P, Gallo JM.
Journal of Pharmacology and Experimental Therapeutics. 2003 Jun;305(3):833-9.

2002

Cells designed to deliver anticancer drugs by apoptosis.
Ma J, Reed K, Gallo JM.
Cancer Research. 2002 Mar 1;62(5):1382-7.

2001

Pharmacodynamic mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP 470.
Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM.
Cancer Research. 2001 Jul 15;61(14):5491-8.

2000

Population pharmacokinetic model for topotecan derived from phase I clinical trials.
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD.
Journal of Clinical Oncology. 2000 Jun;18(12):2459-67.

1996

Uptake of temozolomide in a rat glioma model in the absence and presence of the angiogenesis inhibitor TNP 470.
Devineni D, Klein Szanto A, Gallo JM.
Cancer Research. 1996 May 1;56(9):1983-7.

1995

Time dependent pharmacodynamic models in cancer chemotherapy: Population pharmacodynamic model for glutathione depletion following administration of buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Gallo JM, Brennan J, Halbher T, Laub P, Ozols RF, O’Dwyer PJ.
Cancer Research. 1995 Oct 15;55(20):4507-11.